MDxHealth is trading 9.92% lower at $0.19 after suspending 2026 revenue guidance following a preliminary Q3 revenue miss. - Preliminary Q3 revenue was approximately $22.7 million, below expectations. - The company cited unexpected sales-force turnover after discontinuing Resolve mdx. - BTIG cut its rating to Neutral from Buy; Lake Street lowered its rating to Hold and cut its price target.